Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease

Journal of Neurochemistry

Volumn 86, Issue 1, 2003, Pages 267-272

  Klivenyi, Peter ^a   Ferrante, Robert J ^a,b   Gardian, Gabrielle ^a   Browne, Susan ^a   Chabrier, Pierre Etienne ^c   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Institut Henri Beaufour   (France)

Author keywords

Experimental therapeutics; Huntington; Inflammation; Neurodegeneration; Oxidative damage; Transgenic mice

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIOXIDANT; BN 82451; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ATROPHY; CELL NUCLEUS INCLUSION BODY; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; HUNTINGTON CHOREA; INFLAMMATION; LIPID PEROXIDATION; MOTOR PERFORMANCE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; HUNTINGTON DISEASE; INCLUSION BODIES; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURONS; NEUROPROTECTIVE AGENTS; SURVIVAL RATE; TREATMENT OUTCOME; UBIQUITIN;

ANIMALIA; MUS MUSCULUS;

EID: 0037971143     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.t01-1-01868.x     Document Type: Article

References (23)

1. Beal M. F. (1995) Aging, energy and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38, 357-366.
2. Bogdanov M., Brown R. H., Matson W., Smart R., Hayden D., O'Donnell H., Flint Beal M. and Cudkowicz M. (2000) Increased oxidative damage to DNA in ALS patients. Free Radic. Biol. Med. 29, 652-658.
3. Bogdanov M. B., Andreassen O. A., Dedeoglu A., Ferrante R. J. and Beal M. F. (2001) Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J. Neurochem. 79, 1-5.
4. Cha J. H. (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23, 387-392.
5. Chabrier P. E., Roubert V., Harnett J., Cornet S., Delafotte S., Charnet-Roussillot C., Spinnewyn B. and Auguet M. (2001) New neuroprotective agents are potent inhibitors of mitochondrial toxins: in vivo and in vitro studies. Soc. Neurosci. Abstr. 27, 530.
6. Chen M., Ona V. O., Li M., Ferrante R. J., Fink K. B., Zhu S., Bian J., Guo L., Farrell L. A., Hersch S. M., Hobbs W., Vonsattel J. P., Cha J. H. and Friedlander R. M. (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of huntington disease. Nature Med. 6, 797-801.
7. Dedeoglu A., Jeitner T. M., Matson S. A., Kubilus J. K., Bogdanov M., Kowall N. W., Matson W. R., Cooper A. L., Ratan R. R., Beal M. F., Hersch S. M. and Ferrante R. J. (2002) Therapeutic effects of the transglutaminase inhibitor, cystamine, in a murine model of Huntington's disease. J. Neurosci. 22, 8942-8950.
8. Dunah A. W., Jeong H., Griffin A., Kim Y. M., Standaert D. G., Hersch S. M., Mouradian M. M., Young A. B., Tanese N. and Krainc D. (2002) Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2, 2.
9. Ferrante R. J., Andreassen O. A., Jenkins B. G., Dedeoglu A., Kuemmerle S., Kubilus J. K., Kaddurah-Daouk R., Hersch S. M. and Beal M. F. (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20, 4389-4397.
10. Ferrante R. J., Andreassen O. A., Dedeoglu A., Ferrante K. L., Jenkins B. G., Hersch S. M. and Beal M. F. (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22, 1592-1599.
11. Li S. H., Cheng A. L., Zhou H., Lam S., Rao M., Li H. and Li X. J. (2002) Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell Biol. 22, 1277-1287.
12. Luthi-Carter R., Strand A., Peters N. L., Solano S. M., Hollingsworth Z. R., Menon A. S., Frey A. S., Spektor B. S., Penney E. B., Schilling G., Ross C. A., Borchelt D. R., Tapscott S. J., Young A. B., Cha J. H. and Olson J. M. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet. 9, 1259-1271.
13. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S. W. and Bates G. P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506.
14. Nucifora F. C. Jr, Sasaki M., Peters M. F., Huang H., Cooper J. K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V. L., Dawson T. M. and Ross C. A. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423-2428.
15. Ona V. O., Li M., Vonsattel J. P., Andréws L. J., Khan S. Q., Chung W. M., Frey A. S., Menon A. S., Li X. J., Stieg P. E., Yuan J., Penney J. B., Young A. B., Cha J. H. and Friedlander R. M. (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399, 263-267.
16. Panov A. V., Gutekunst C. A., Leavitt B. R., Hayden M. R., Burke J. R., Strittmatter W. J. and Greenamyre J. T. (2002) Early mitochondrial calcium defects in Huntington's disease area direct effect of polyglutamines. Nat. Neurosci. 1, 1.
17. Perez-Severiano F., Rios C. and Segovia J. (2000) Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res. 862, 234-237.
18. Sapp E., Kegel K. B., Aronin N., Hashikawa T., Uchiyama Y., Tohyama K., Bhide P. G., Vonsattel J. P. and DiFiglia M. (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60, 161-172.
19. Singhrao S. K., Neal J. W., Morgan B. P. and Gasque P. (1999) Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp. Neurol. 159, 362-376.
20. Steffan J. S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y. Z., Gohler H., Wanker E. E., Bates G. P., Housman D. E. and Thompson L. M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA 97, 6763-6768.
21. Tabrizi S. J., Workman J., Hart P. E., Mangiarini L., Mahal A., Bates G., Cooper J. M. and Schapira A. H. (2000) Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 47, 80-86.
22. Wyttenbach A., Sauvageot O., Carmichael J., Diaz-Latoud C., Arrigo A. P. and Rubinsztein D. C. (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 11, 1137-1151.
23. Zeron M. M., Hansson O., Chen N., Wellington C. L., Leavitt B. R., Brundin P., Hayden M. R. and Raymond L. A. (2002) Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33, 849-860.